Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Breast Cancer Res Treat. 2023 Apr 15;199(3):589–601. doi: 10.1007/s10549-023-06937-9

Fig. 3.

Fig. 3.

Differential expression analysis of ER+ patients above the 75th percentile of RET and GDNF expression (high RET/GDNF) relative to all other ER+ patients demonstrated by a (A) volcano plot of all genes with significantly upregulated and downregulated genes having L2FC > 1 and < −1 respectively along with FDR < 0.05 and (B) heatmap of top 40 significant upregulated and downregulated differentially expressed genes defining high RET/GDNF ER+ tumors.